Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA C420R |
| Therapy | ZM-PI05 |
| Indication/Tumor Type | Her2-receptor positive breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA C420R | Her2-receptor positive breast cancer | sensitive | ZM-PI05 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ZM-PI05 induced cell cycle arrest and decreased viability of an ERBB2 (HER2)-positive breast cancer cell line harboring PIK3CA C420R in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38986734). | 38986734 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38986734) | PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. | Full reference... |